Loading…
Loading…
Accelerant (NYSE: ARX - Get Free Report) and Employers (NYSE: EIG - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Profitability This table compares Accelerant and Employers' net margins, return
Investors need to pay close attention to ARX stock based on the movements in the options market lately.
Accelerant Holdings (NYSE: ARX - Get Free Report) has been assigned an average rating of "Hold" from the twelve ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have assigned a buy recommendation to the company. The
Accelerant (NYSE: ARX - Get Free Report) and Hagerty (NYSE: HGTY - Get Free Report) are both mid-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Valuation and Earnings This table compares Accelerant and Hagerty"s
ATLANTA--(BUSINESS WIRE)--Accelerant Announces Expiration of “Go-Shop” Period.
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026Insiders may stand to receive substantial financial benefits
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a law firm representing investors in securities and corporate governance matters, is investigating the proposed sale of Accelerant Holdings (NYSE: ARX) to private equity firm Thoma Bravo for $20.25 per share.
Accelerant Holdings NYSE: ARX jumped into view for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, not for an unglamorous firm connecting specialty insurance risk across a network of capital providers.